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Abstract Genetic counseling and BRCA1/BRCA2 genes
testing are routinely offered in a clinical setting. However,
no data are available on the proportion of breast cancer
patients with a positive family history undergoing genetic
counseling. By linking databases of the Oncogenetics and
Cancer Prevention Unit at the Geneva University Hospitals
and the population-based Geneva Cancer Registry, we
evaluated the uptake of genetic counseling among 1709
breast cancer patients with familial risk of breast cancer and
the determinants of such a consultation process. We also
studied the impact of genetic counseling on contralateral
breast cancer occurrence and survival. Overall, 191 (11.2 %)
breast cancer patients had genetic counseling; this propor-
tion was 25.1 % within the high familial risk group. Recent
period of diagnosis, early-onset breast cancer, female off-
spring, high familial risk, tumor size, and chemotherapy
treatment were statistically significantly associated with
genetic counseling uptake in multivariate analysis. More
than 2 % of patients had developed contralateral metachro-
nous breast cancer. An increased risk of contralateral breast
cancer of borderline significance was found for patients who
had genetic counseling versus those who had not (Cox model
adjusted hazard ratio 2.2, 95 % confidence intervals 1.0–5.2,
P = 0.063). Stratification by BRCA1/BRCA2 mutation sta-
tus showed that the occurrence of contralateral breast cancer
was 8-fold higher among mutation carriers compared with
non-carriers. Age-adjusted overall survival and breast can-
cer-specific survival were not significantly different between
patients who underwent genetic counseling and those who
did not. In conclusion, we observed a significant increase in
the use of genetic counseling over time and found that breast
cancer patients with high familial risk had more often
genetic counseling than those with moderate familial risk. A
more thorough evaluation of sociodemographic and clinical
predictors to attend the cancer genetic unit may help
improving the use of genetic counseling services for at-risk
individuals at a population level.
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Introduction
Positive family history is one of the strongest predictors of
a woman’s lifetime risk of developing breast cancer [1, 2].
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BRCA1 and BRCA2 are the two major susceptibility genes
involved in hereditary predisposition to breast cancer [3,
4]. Genetic counseling and testing are now routinely
offered to individuals with increased probability of carry-
ing BRCA1/BRCA2 mutations [5]. Therefore, breast cancer
patients and their relatives dealing with the possibility of
hereditary breast cancer risk have to face numerous deci-
sions, including the choice of undergoing genetic coun-
seling, testing for BRCA1 and BRCA2 mutations,
screening, and prevention strategies such as chemopre-
vention and prophylactic surgery. Family history of breast
cancer is also a well-established risk factor for contralateral
breast cancer [6–10]. Carrying BRCA1/BRCA2 germ-line
mutations has been associated with a high risk of contra-
lateral breast cancer with a 10-year risk ranging from 18 to
33 % for BRCA1 mutation carriers and from 13 to 19 % for
BRCA2 mutation carriers [11–14]. To date, no study
investigated the impact of genetic counseling among breast
cancer patients with familial risk on breast cancer outcome.
Robust data exist on the uptake rate and determinants of
BRCA1/BRCA2 testing in families diagnosed with delete-
rious BRCA1/BRCA2 mutations [15–20]. Rates of testing
among first- and second-degree relatives of index cases
ranged from 27 to 44 %, and testing decision was more
frequent among females, first-degree relatives, individuals
with personal history of cancer, and individuals with off-
spring [15–17, 19, 20]. On the contrary, little is known
about the attendance rates and determinants of genetic
counseling and testing in different populations, and the
context according to personal and family history of breast
cancer. In a systematic review evaluating the real and the
hypothetical (defined as ‘‘being interested in testing’’)
uptake of breast cancer genetic testing in individuals with
personal or family breast cancer history, a few character-
istics such as Ashkenazi Jewish heritage, older age, and
married status were associated with genetic testing uptake
[21]. However, studies differed in recruitment setting,
assessment of family history of breast cancer and uptake
definitions. In particular, none of the previous studies has
evaluated on a population-based level, the effects of other
potentially important characteristics such as social class,
private or public sector of care, and tumor characteristics in
genetic counseling attendance and the effect of such con-
sultation on breast cancer outcome [21–24].
The main goals of the present study were to assess the
proportion of breast cancer patients with a positive family
history who decided to undergo genetic counseling in a
population-based setting and to investigate the determi-
nants of such a consultation process. We also investigated
the impact of counseling uptake on breast cancer outcomes
including contralateral tumor occurrence and survival.
These issues were addressed by linking databases of the
Oncogenetics and Cancer Prevention Unit at the Geneva
University Hospitals and the population-based Geneva
Cancer Registry in Switzerland.
Patients and methods
Oncogenetics and Cancer Prevention Unit and Geneva
Cancer Registry databases
In 1994, a consultation unit providing cancer risk assess-
ment, surveillance, and prevention recommendations was
initiated by the Division of Oncology at the Geneva Uni-
versity Hospitals, Switzerland. It was formally set up as the
Oncogenetics and Cancer Prevention Unit in 1996, and
remained the only center providing genetic counseling for
familial aggregation or hereditary breast cancer predispo-
sition syndromes in the Geneva area. The counseling
activity encompasses all levels of care (average, as well as
moderate, and high cancer risk situations) and all types of
familial cancer aggregation or hereditary cancer suscepti-
bility syndromes. The cancer risk evaluation process
involves the collection of personal and family history (at
least for first-, second-, and third-degree relatives) and,
whenever possible, confirmation of all cancer diagnoses
through medical records. In case of personal or familial
medical history suggestive of a hereditary cancer suscep-
tibility syndrome, the possibility to undergo genetic testing
is extensively discussed as part of the genetic counseling.
Since 1994, more than 1,800 families have been seen at the
Oncogenetics Unit and about 60 % of all probands con-
sulted for breast cancer risk evaluation.
For the purpose of this study, 1,550 pedigrees of indi-
viduals (probands) who consecutively consulted the Onc-
ogenetics and Cancer Prevention Unit between 1994 and
15 June 2012 were reviewed and all breast cancer diag-
noses were registered. After having confirmed with the
Geneva Cancer Registry that the residence of the patient
and the site of breast cancer-related treatments were loca-
ted in the Geneva Canton, a total of 469 individuals were
retained for the study. Variables of interest included in this
database are gender, date of birth, vital status, parity, date
of breast cancer diagnosis, relationship with the family
member attending genetic consultation, date of first con-
sultation, carrying out BRCA1/BRCA2 testing, date of
blood sampling, and genetic testing result. For the carriers
of pathogenic BRCA1 or BRCA2 mutations, information
concerning preventive mastectomy and/or oophorectomy
(realized or not, and when relevant, age at surgery) was
also considered.
The population-based Geneva Cancer Registry has been
described in detail elsewhere [25]. Briefly, the database
contains information on all patients with cancer diagnosed
in the resident population of the canton of Geneva since
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1970. The Geneva Cancer Registry extracts information
from various sources and is considered accurate [26].
Recorded data include sociodemographic information,
history of breast and ovarian cancers in first- or second-
degree relatives, tumor characteristics [27], hormone
receptor status, stage of disease at diagnosis, treatment
during the first 6 months after diagnosis, occurrence of
other primary cancers, and survival status. The Cancer
Registry regularly assesses survival. The index date refers
to the date of diagnosis confirmation or the date of hospi-
talization when it preceded the diagnosis and was related to
the disease. In addition to passive follow-up (routine
examination of death certificates and hospital records),
active follow-up is performed yearly using the files of the
Cantonal Population Office in charge of the registration of
the resident population. Cause of death is systematically
recorded and validated by consulting medical files or, when
necessary, by sending a specific questionnaire to the
patient’s physician. Cause of death is coded according to
the International Statistical Classification of Diseases and
Related Health problems [28].
Variables of interest included in this database are patient
characteristics (date of diagnosis, age at diagnosis, marital
status, offspring, level of familial risk, social class, country
of birth, sector of care), tumor characteristics (method of
detection, stage, size, axillary node involvement, histologi-
cal subtype, differentiation, hormone receptor status, and
HER2 status), types of treatment (surgery, radiotherapy,
chemotherapy, and hormonotherapy), and outcome.
Social class was regrouped in three levels: low (manual
employees, skilled and unskilled workers), middle (non-
manual employees and administrative staff), and high
(professionals, executives, administrators, entrepreneurs)
based on the patient’s last occupation or, if unemployed,
that of the spouse.
Breast cancer histology was classified as ductal carci-
noma, lobular carcinoma, other and unknown (no micro-
scopic confirmation). Staging was based on the pathologic
tumor-node-metastasis (TNM) classification or, when
absent, the clinical TNM classification [28]. Hormone
receptor status was classified as positive (C1 % cells
expressing receptors) or negative (\1 % cells expressing
receptors). Treatment was classified as surgery (breast-
conservative surgery, mastectomy), radiotherapy (yes, no),
chemotherapy (yes, no), and hormonotherapy (yes, no).
History of breast and ovarian cancers in first- or second-
degree relatives is routinely recorded since 1990 [29].
Familial risk was categorized as high (at least 1 first-degree
relative with breast/ovarian cancer diagnosed before the age
of 50 years, or at least 2 first-degree relatives with breast/
ovarian cancer at any age, or at least three cases of breast/
ovarian cancer among first- or second-degree relatives), low
(no affected first- or second-degree relatives with breast/
ovarian cancer), or moderate (all other known family his-
tories) according to a previous study of our group [29].
For the purpose of the current study, we identified all
women with a first invasive breast cancer and a moderate
or high familial risk recorded between 1990 and 2010 at the
Geneva Cancer Registry (n = 1784). Linkage of this
database with the one of Oncogenetics and Cancer Pre-
vention Unit (n = 469) led us to exclude 203 individuals
from the latter (9 male patients, 11 breast cancer patients
diagnosed before 1990, 33 patients with in situ carcinoma
and 150 patients classified as low familial risk). Finally, 75
women who had not themselves undergone genetic coun-
seling were excluded from both databases.
Statistical analysis
We compared patient, tumor, and treatment characteristics
among women who had genetic counseling versus women
who had not using the Chi square test of heterogeneity. To
assess which variables were independently associated from
genetic consultation, we performed an unconditional
logistic regression including in the model variables sig-
nificantly associated in univariate analyses. Breast cancer
patients who had genetic counseling were considered as
cases and those who had not as controls.
Patients were followed for occurrence of metachronous
contralateral breast cancer or death until December 31,
2010. Metachronous contralateral breast cancers were
defined as all invasive breast cancers occurring after
6 months following the first breast cancer. Cumulative
risks for developing metachronous contralateral breast
cancer after the first breast cancer were calculated by using
the Kaplan–Meier product-limit method and were com-
pared between patients with and without genetic counsel-
ing by using the log-rank test. Cox proportional hazards
regression was used to calculate hazard ratios and their
95 % confidence intervals (95 % CI). Observations were
censored at the time of contralateral breast cancer, or death,
whichever occurred first. Patients with synchronous con-
tralateral cancer at the time of first breast cancer (n = 34)
or having had a prophylactic bilateral mastectomy
(n = 43) were excluded from this analysis.
We also evaluated the breast cancer-specific survival
defined as the interval between the date of diagnosis and
the date of death from breast cancer, and the overall sur-
vival defined as the interval between the date of diagnosis
and the date of death from any cause. We used Cox
regression models to evaluate the impact on survival of
having genetic counseling.
All tests were two-sided. Statistical significance was
established at P \ 0.05. Analyses were performed using
SPSS software (version 15.0.1, SPSS Inc. Chicago, IL,
USA).
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Results
The studied cohort included 1,709 breast cancer patients
with moderate or high familial risk, 191 (11.2 %) had
genetic counseling, and 1,518 (88.8 %) never had one. The
mean duration of follow-up was not significantly different
between patients who underwent genetic counseling and
those who did not (79 months and 86 months, respectively;
P = 0.095). Among the 191 patients who had genetic
counseling, 119 (62.3 %) underwent BRCA1/BRCA2
genetic testing. Out of this group, pathogenic mutations
were identified in 23 (19.3 %) patients, whereas the
remaining 96 patients had non-informative testing results.
Fifteen patients carried a BRCA1 mutation and eight
patients a BRCA2 mutation.
Determinants of genetic counseling uptake
Characteristics of the entire patients’ cohort are presented
in Table 1. Genetic counseling uptake increased from
8.4 % (20/238) for patients diagnosed in 1990–1994 to
16.3 % (91/560) for those diagnosed in 2005–2010,
whichever was the date of genetic consultation. Among
high familial risk patients, 25.1 % (94/374) had genetic
counseling versus 7.3 % (97/1335) of patients belonging to
moderate-risk group (P \ 0.001). Compared to patients
without genetic counseling, those who underwent genetic
counseling were significantly younger (mean, 49.5 years vs
60.0 years, P \ 0.001), of higher social class (P = 0.036),
had more often female offspring (P \ 0.001) and a higher
familial risk (P \ 0.001). Statistically, significant differ-
ences in family history between patients who underwent
genetic counseling and those who did not were noted:
53.9 % of counseled patients versus 24.8 % of uncounseled
patients had two or more first- or second-degree relatives
affected by breast/ovarian cancer (P \ 0.001); these fig-
ures were 14.1 and 4.6 %, respectively, when considering
affected first-degree relatives only (P \ 0.001). Patients
who had genetic counseling had significantly more often
tumors of smaller size (P = 0.001) and received more
often chemotherapy (P \ 0.001) than uncounseled
patients. To assess which variables were independently
associated with the uptake of genetic counseling, we
included in a logistic regression model all variables sig-
nificantly linked to genetic counseling attendance in uni-
variate analyses (i.e., period of diagnosis, age at diagnosis,
social class, female offspring, familial risk, tumor size, and
chemotherapy). Patients with a significantly higher proba-
bility of having genetic counseling were those diagnosed in
2005–2010 compared to those diagnosed in 1990–1994
(odds ratio [OR] 2.2, 95 % CI 1.2–4.0), those with female
offspring versus those without (OR 2.0, 95 % CI 1.4–2.9),
those with high familial risk versus those with moderate
familial risk (OR 5.1, 95 % CI 3.6–7.1), and those with
versus without chemotherapy (OR 1.8, 95 % CI 1.2–2.6)
(Table 2). By contrast, the ORs for genetic counseling use
were significantly decreased for patients aged 50–69 years
(OR 0.4, 95 % CI 0.3–0.5) or aged 70 years or more (OR
0.1, 95 % CI 0.1–0.3) compared with patients under
50 years of age. We performed sensitive analyses by add-
ing in the model the four variables found with a P value
between 0.05 and 0.10 in univariate analysis (i.e., method
of breast cancer detection, tumor differentiation, surgery,
and radiotherapy) and also using a backward stepwise
logistic regression including all the 21 parameters studied
in Table 1. The results were unchanged or were not mod-
ified. None of the interactions tested was significant: the
P values were 0.93 for interaction between social class and
age, 0.97 for interaction between tumor size and chemo-
therapy, 0.96 for interaction between tumor size and
radiotherapy, and 0.46 for interaction between tumor size
and surgery.
Impact of genetic counseling uptake on breast cancer
outcome
In total, 1,632 patients with a previous unilateral breast
cancer diagnosis were included in the analysis of contra-
lateral metachronous breast cancer. Among the 191
patients who underwent genetic counseling, ten women
were excluded (four had synchronous bilateral breast can-
cer and six had contralateral preventive mastectomy asso-
ciated to primary breast surgery). A total of 36 patients
(2.2 %) had developed a contralateral invasive breast
cancer in a median period of 2,363 days (range
430–5,984). The hormonal status of both first and second
breast tumors was known for 24 of these 36 patients. A
moderate agreement was found for the estrogen receptor
status (kappa = 0.44, P = 0.028) whereas no agreement
between the first and second tumors was observed for the
progesterone receptor status (kappa = 0.08, P = 0.63).
Table 3 shows patient, tumor, and treatment characteristics
significantly associated with metachronous contralateral
breast cancer occurrence in a univariate analysis. Genetic
counseling use, diagnosis of cancer in the earlier periods,
younger age at diagnosis, high familial risk, larger tumor
size, mastectomy, lack of estrogen receptor of the first
tumor, the absence of hormonotherapy (which is linked to
estrogen receptor status) appeared as risk factors for the
development of metachronous contralateral breast cancer
in our study. Cumulative risks for developing metachro-
nous contralateral breast cancer after the first diagnosis
were significantly different between patients who under-
went a genetic consultation versus those who did not
(logrank test P \ 0.001, Fig. 1). The delay for contralateral
breast cancer occurrence was similar for patients with
382 Breast Cancer Res Treat (2014) 144:379–389
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Table 1 Characteristics of
breast cancer patients with
increased familial risk
according to uptake of genetic
counseling
Genetic counseling Pa
Yes, n = 191 No, n = 1,518
No. (%) No. (%)
Patient characteristics
Period of cancer diagnosis \0.001
1990–1994 20 (11) 218 (14)
1995–1999 27 (14) 380 (25)
2000–2004 53 (28) 451 (30)
2005–2010 91 (48) 469 (31)
Age at diagnosis, years \0.001
\50 98 (51) 348 (23)
50–69 82 (43) 811 (53)
C70 11 (6) 359 (24)
Marital status 0.971
Ever married 162 (85) 1,286 (85)
Never married 29 (15) 232 (15)
Female offspringb \0.001
No 68 (36) 858 (57)
Yes 123 (64) 660 (44)
Familial risk \0.001
Moderate 97 (51) 1,238 (82)
High 94 (49) 280 (18)
Social class 0.036
High 51 (29) 276 (20)
Medium 97 (55) 834 (61)
Low 30 (17) 253 (19)
Unknown 13 (-) 155 (–)
Country of birth 0.591
Switzerland 98 (51) 824 (54)
Southern Europe 52 (27) 363 (24)
Other 41 (22) 331 (22)
Sector of care 0.297
Private 90 (47) 776 (51)
Public 101 (53) 742 (49)
Tumor characteristics
Method of detection 0.071
Symptoms 34 (18) 358 (24)
Breast self-examination 73 (38) 477 (31)
Clinical screening 10 (5) 125 (8)
Mammography 74 (39) 558 (37)
Stage 0.980
I 80 (43) 630 (43)
II 81 (43) 634 (43)
III 21 (11) 168 (11)
IV 5 (3) 48 (3)
Unknown 4 (–) 38 (–)
Axillary node 0.130
Negative 101 (54) 883 (60)
Positive 86 (46) 594 (40)
Unknown 4 (–) 41 (–)
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genetic counseling and for those without genetic counsel-
ing (2,550 and 3,194 days, respectively; P = 0.298). In a
Cox model accounting for other variables significantly
associated with contralateral breast cancer occurrence (i.e.,
period of diagnosis, age at diagnosis, familial risk, tumor
size, breast surgery and hormonotherapy), the risk (hazard
ratio [HR]) for a contralateral breast cancer for patients
with versus without genetic counseling was 2.2 (95 % CI
1.0–5.2, P = 0.063). Further adjustment on other potential
determinants of metachonous breast cancer, including
Table 1 continued
a v2 test of heterogeneity
b Extracted from the Cantonal
Population Office
c Recorded since 1995
d Recorded since 2001
Genetic counseling Pa
Yes, n = 191 No, n = 1,518
No. (%) No. (%)
Histological subtype 0.436
Ductal 160 (84) 1,218 (80)
Lobular 23 (12) 207 (14)
Other 8 (4) 93 (6)
Differentiation 0.051
Good 47 (26) 397 (28)
Moderate 81 (44) 707 (50)
Poor 56 (30) 318 (22)
Unknown 7 (–) 96 (–)
Size, mm 0.001
1–20 121 (78) 858 (65)
21–40 23 (15) 379 (29)
[40 11 (7) 90 (7)
Unknown 36 (–) 191 (–)
Estrogen receptor statusc 0.204
Positive 141 (84) 1,106 (87)
Negative 27 (16) 159 (13)
Unknown 23 (–) 253 (–)
Progesterone receptor statusc 0.429
Positive 125 (74) 979 (77)
Negative 43 (26) 290 (23)
Unknown 23 (–) 249 (–)
HER2 receptor statusd 0.446
Positive 20 (16) 137 (19)
Negative 103 (84) 578 (81)
Unknown 68 (–) 803 (–)
Treatment characteristics
Surgery 0.096
No 4 (2) 89 (6)
Mastectomy 51 (27) 393 (26)
Breast conserving 136 (71) 1,036 (68)
Radiotherapy 0.096
No 32 (17) 334 (22)
Yes 159 (83) 1,184 (78)
Chemotherapy \0.001
No 74 (39) 920 (61)
Yes 117 (61) 598 (39)
Hormonotherapy 0.966
No 53 (28) 419 (28)
Yes 138 (72) 1,099 (72)
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social class, sector of care, method of breast cancer
detection, tumor differentiation, surgery, and radiotherapy,
yielded a HR 2.0 (95 % CI 0.9–4.9, P = 0.108).
Among the 181 patients who benefited from genetic
counseling included in the analysis of contralateral
metachronous breast cancer, 111 (61.3 %) performed
genetic testing and 18 of them (16.2 %) carried BRCA1/
BRCA2 germ-line mutations. Stratification by BRCA1/
BRCA2 mutation status showed that the occurrence of
contralateral breast cancer was 8-fold higher among
mutation carriers than among non-carriers (33 vs 4 %,
P \ 0.001). The risk of developing a contralateral breast
cancer for patients with versus without BRCA1/BRCA2
mutations was significantly higher (crude HR 10.5, 95 %
CI 2.9–38.5, P \ 0.001).
The overall survival did not significantly differ between
patients who underwent genetic counseling and those who
did not (age-adjusted HR 0.8, 95 % CI 0.5–1.3,
P = 0.906). Similarly, breast cancer-specific survival was
not significantly different between the two groups (age-
adjusted HR 0.8, 95 %CI 0.5–1.4, P = 0.484).
Discussion
To our knowledge, this is the first population-based study
assessing the rate of genetic counseling uptake among
breast cancer patients with a positive family history and to
demonstrate the impact of such counseling on breast cancer
outcome. This study has been carried out with the support
of the Oncogenetics and Cancer Prevention Unit, which is
the only center providing genetic consultation since 1994
for breast cancer familial aggregation or hereditary pre-
disposition syndromes, and the Geneva Cancer Registry,
which is the oldest registry in Switzerland to collect and
analyze cancer data for the entire population of Geneva. In
Switzerland, modalities of breast cancer treatment are
Table 2 Adjusted odds ratio (OR) for the uptake of genetic
counseling
Variables Adjusted ORa (95 % CI) P(heterogeneity)
Period of diagnosis
1990–1994 1 (Reference) 0.001
1995–1999 0.8 (0.4–1.6)
2000–2004 1.3 (0.7–2.5)
2005–2010 2.2 (1.2–4.0)**
Age at diagnosis, years
\50 1 (Reference) \0.001
50–69 0.4 (0.3–0.5)***
C70 0.1 (0.1–0.3)***
Social class
High 1 (Reference) 0.406
Medium 0.8 (0.5–1.2)
Low 0.7 (0.4–1.2)
Female offspring
No 1 (Reference) \0.001
Yes 2.0 (1.4–2.9)***
Familial risk
Moderate 1 (Reference) \0.001
High 5.1 (3.6–7.1)***
Tumor size, mm
1–20 1 (Reference) 0.004
21–40 0.4 (0.3–0.7)**
[40 0.9 (0.4–1.9)
Chemotherapy
No 1 (Reference) 0.004
Yes 1.8 (1.2–2.6)**
a Adjusted for all other variables
* P \ 0.05; ** P \ 0.01; *** P \ 0.001
Table 3 Factors associated with occurrence of metachronous con-
tralateral breast cancer
Variables n Metachronous
contralateral
breast cancer n (%)
Pa
Genetic counseling
No 1,451 26 (1.8) 0.001
Yes 181 10 (5.5)
Period of diagnosis
1990–1994 229 9 (3.9) 0.001
1995–1999 386 15 (3.9)
2000–2004 482 10 (2.1)
2005–2010 535 2 (0.4)
Age at diagnosis, years
\50 426 15 (3.5) 0.021
50–69 857 19 (2.2)
C70 349 2 (0.6)
Familial risk
Moderate 1,278 22 (1.7) 0.011
High 354 14 (4.0)
Tumor size, mm
1–20 945 15 (1.6) 0.022
21–40 377 9 (2.4)
[40 94 6 (6.4)
Unknown 216 6 (2.8)
Surgery
No 91 0 (0.0) 0.044
Mastectomy 384 14 (3.6)
Breast conservation 1,157 22 (1.9)
Hormonotherapy
No 452 18 (4.0) 0.002
Yes 1,180 18 (1.5)
a v2 test of heterogeneity; univariate analysis
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chosen by a multidisciplinary staff including surgeons,
chemo- and radiotherapists according to the international
clinical guidelines. Procedures are the same in the public
and the private sectors of care. Accordingly, all patients are
offered the same options of treatment at first issue. Glob-
ally, 11.2 % of breast cancer patients that could potentially
benefit from genetic counseling were effectively seen at the
Oncogenetics and Cancer Prevention Unit. The geographic
dispersal of some of the families and the cosmopolitan
characteristics of the Geneva population with an important
turn-over may partially explain this low proportion of
uptake compared to less mobile populations. It is possible
that some of breast cancer patients sought counseling
somewhere out of the Geneva canton, so that 11.2 % would
be a conservative estimate. Approximately, one out of four
high familial risk breast cancer patients underwent genetic
counseling. In our opinion, this is an important result since
consultation process, genetic analysis, and specific sur-
veillance/preventive measures are mostly addressed to
high- rather than moderate-breast cancer risk patients. Our
data are consistent with previous studies that found a sta-
tistically significant association between having a positive
family history and hypothetical or real uptake of BRCA1/
BRCA2 genetic testing [21, 30, 31].
In this study, we showed that recent period of breast
cancer diagnosis, young age at diagnosis, female offspring,
and high familial risk were statistically significant deter-
minants of genetic counseling uptake. The increasing use
of genetic counseling over time has previously been
reported [32]. This is not surprising considering the better
knowledge on prevalence and penetrance of BRCA1/
BRCA2 mutations [14, 33–38], the impact of risk man-
agement recommendations on breast cancer prevention and
mortality [39, 40], and the growing interest in genetics
showed by physicians and general population. Therefore, it
is anticipated that a higher proportion of breast cancer
patients and their relatives will benefit from appropriate
clinical recommendations in the future. Early-onset breast
cancer is a criterion to refer patients to genetic counseling
[41–43]. Thus, it was expected that breast cancer patients
years 
 with genetic counseling  
without genetic counseling
Cumulative risk 
Curves were calculated using the Kaplan-Meier method; logrank test P<0.001.
Genetic counseling 0-3 years 4-7 years 8-11 years 12-15 years
n Obs n Obs n Obs n Obs
No 1451 5 1082 10 656 7 330 2
Yes 181 2 119 2 66 2 33 2
n is the number of persons at risk at the beginning of the period of follow-up. Obs is the 
number of observed cases of metachronous contralateral breast cancer during the period of 
follow-up.
This figure did not include 4 cases of metachronous contralateral breast cancer occurring 
after a follow-up period of over 15 years (2 in the group with genetic counselling and 2 in the 
group without genetic counselling) because of the small number of persons remaining at risk.
Fig. 1 Cumulative risk for
metachronous contralateral
breast cancer according to
uptake of genetic counseling
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diagnosed before 50 years of age were more likely to
undergo genetic counseling than patients diagnosed after
50 years of age. The association between genetic coun-
seling uptake and female offspring found in our study is in
agreement with results from previous studies on predictive
BRCA1/BRCA2 genetic testing [15–20]. These studies
showed that one of the currently reported motivations to
undergo genetic counseling is to determine the cancer risk
of the offspring, which may in the future have an impact on
their clinical surveillance.
With regard to a possible association between social
class levels and use of genetic counseling, we cannot
exclude that patients belonging to lower socio-economic
classes could be less concerned by genetic counseling and
medical screening than individuals of higher social level.
Of note, this type of medical consultation, as well as the
cost of testing for most of the cancer genetic predisposition
syndromes, is covered by the mandatory health insurance
system for all Swiss citizens. Consequently, in our opinion,
genetic counseling-related costs per se would not or little
influence the decision to uptake genetic counseling. The
fact that genetic counseling uptake was higher among
patients with high social level could be related to a more
effective communication process between the physicians
and their patients. Noteworthy, receiving chemotherapy
treatment was another factor associated with the uptake of
genetic counseling. This result could reflect a particular
awareness about genetic and familial risk of medical on-
cologists compared to other physicians [44]. It could also
reflect a heightened awareness regarding more adequate or
more complete cancer treatment among breast cancer
patients with affected family members who underwent
genetic counseling.
We found a twofold higher risk of metachronous con-
tralateral breast cancer among patients with genetic coun-
seling uptake than for those without. This result is consistent
with the fact that early-onset disease and strong positive
family history are both criteria to refer people to genetic
evaluation and that they are well-established risk factors for
contralateral breast cancer [7, 8, 10, 45]. However, it could
also be a consequence of a more intensive surveillance
program/self-observation recommended by genetic consul-
tants to moderate- and high-risk patients. Notably, in five out
of 10 patients who underwent genetic counseling and
developed metachronous breast cancer, contralateral cancer
diagnosis occurred after the genetic consultation process and
all of these patients followed an enhanced surveillance.
No significant differences in overall survival and in
breast cancer-specific survival were observed between
patients with and without genetic counseling uptake.
Despite a study period of 20 years, the number of deaths
from breast cancer was limited among patients who had
genetic counseling (n = 15) and, accordingly, the
statistical power was low to detect differences between the
two groups.
The main limitation of the study is the fact that infor-
mation concerning cancer family history was extracted
from medical files or derived by questioning physicians
and not directly from the patients. The familial risk of
breast cancer was established integrating information
available at the time of cancer diagnosis; therefore, patients
who developed a positive family history after breast cancer
diagnosis could have been missed. Moreover, family
structure/size and details of the concerned branch of the
family were not taken into account to categorize the
familial risk. However, information on family history is
accurate as attested by a previous study of our group [46].
Education is not routinely recorded by the Geneva Cancer
Registry. We used patient’s last occupation, or if unem-
ployed, that of the spouse in order to create a three-level
indicator of socioeconomic status. Occupational social
class and education measures have been shown to be highly
correlated. Despite the fact that the 3 levels of socioeco-
nomic indicators used can only be considered as an
approximate indicator of education level, confounding
from education is likely to be limited.
In conclusion, we evaluated the actual proportion of
breast cancer patients with positive family history of breast
cancer that benefit from genetic counseling and assessed
the clinical outcome in terms of contralateral breast cancer
occurrence and survival in our population. The uptake of
genetic counseling among patients with personal and
family history of breast cancer is notably increasing over-
time. We found a significant proportion of high familial
risk patients effectively undergoing genetic consultation
process. A better knowledge of demographic and clinical
determinants of attending a cancer genetic unit should be
helpful to improve the genetic counseling activity and thus,
to reach more at-risk breast cancer individuals concerned
by effective surveillance and prevention measures.
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